Ultragenyx Pharmaceutical (RARE) Financials

Ultragenyx Pharmaceutical logo
$15.90 -0.18 (-1.12%)
Closing price 04:00 PM Eastern
Extended Trading
$15.84 -0.06 (-0.39%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Ultragenyx Pharmaceutical

Annual Income Statements for Ultragenyx Pharmaceutical

This table shows Ultragenyx Pharmaceutical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-146 -246 -302 -198 -403 -187 -454 -707 -607 -569 -575
Consolidated Net Income / (Loss)
-146 -246 -302 -198 -403 -187 -454 -707 -607 -569 -575
Net Income / (Loss) Continuing Operations
-146 -246 -302 -198 -403 -187 -454 -707 -607 -569 -575
Total Pre-Tax Income
-146 -246 -318 -197 -399 -185 -453 -702 -609 -567 -571
Total Operating Income
-148 -248 -329 -371 -424 -330 -382 -649 -569 -536 -535
Total Gross Profit
0.00 0.13 2.61 50 95 265 335 335 389 483 564
Total Revenue
0.00 0.13 2.61 51 104 271 351 363 434 560 673
Operating Revenue
0.00 0.13 2.61 51 104 271 351 363 434 560 673
Total Cost of Revenue
0.00 0.00 0.00 1.15 9.01 6.13 16 28 45 77 109
Operating Cost of Revenue
0.00 0.00 0.00 1.15 9.01 6.13 16 28 45 77 109
Total Operating Expenses
148 248 332 422 519 595 717 984 958 1,019 1,099
Selling, General & Admin Expense
33 65 100 128 162 183 220 278 310 321 349
Research & Development Expense
115 183 232 294 357 412 497 706 648 698 750
Total Other Income / (Expense), net
2.12 2.17 11 174 25 145 -71 -53 -40 -31 -36
Interest Expense
- - 0.00 0.00 1.14 33 29 43 66 63 62
Interest & Investment Income
2.32 3.79 4.07 9.54 27 177 -40 -8.23 27 37 25
Other Income / (Expense), net
-0.20 -1.62 6.53 165 -0.79 0.61 -1.69 -1.57 -1.00 -5.00 1.00
Income Tax Expense
0.00 0.04 -16 0.51 3.28 1.21 1.04 5.70 -2.00 2.00 4.00
Basic Earnings per Share
($3.96) ($6.21) ($7.12) ($3.97) ($7.12) ($3.07) ($6.70) ($10.12) ($8.25) ($6.29) ($5.83)
Weighted Average Basic Shares Outstanding
36.78M 39.59M 42.45M 49.78M 56.58M 60.85M 67.80M 69.91M 73.50M 90.50M 98.60M
Diluted Earnings per Share
($3.96) ($6.21) ($7.12) ($3.97) ($7.12) ($3.07) ($6.70) ($10.12) ($8.25) ($6.29) ($5.83)
Weighted Average Diluted Shares Outstanding
36.78M 39.59M 42.45M 49.78M 56.58M 60.85M 67.80M 69.91M 73.50M 90.50M 98.60M
Weighted Average Basic & Diluted Shares Outstanding
36.78M 39.59M 42.45M 49.78M 56.58M 60.85M 67.80M 70.22M 82.34M 92.50M 96.63M

Quarterly Income Statements for Ultragenyx Pharmaceutical

This table shows Ultragenyx Pharmaceutical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-171 -132 -134 -133 -151 -115 -180 -129 -185 -92 -118
Consolidated Net Income / (Loss)
-171 -132 -134 -133 -151 -115 -180 -129 -185 -92 -118
Net Income / (Loss) Continuing Operations
-171 -132 -134 -133 -151 -115 -180 -129 -185 -92 -118
Total Pre-Tax Income
-170 -131 -133 -133 -150 -114 -179 -128 -184 -91 -127
Total Operating Income
-165 -116 -132 -122 -143 -108 -171 -113 -169 -75 -110
Total Gross Profit
91 126 118 148 110 144 132 178 106 180 141
Total Revenue
109 147 139 165 139 167 160 207 136 214 173
Operating Revenue
109 147 139 165 139 167 160 207 136 214 173
Total Cost of Revenue
18 21 21 17 29 23 28 29 30 34 32
Operating Cost of Revenue
18 21 21 17 29 23 28 29 30 34 32
Total Operating Expenses
257 242 250 270 253 252 303 291 275 255 251
Selling, General & Admin Expense
78 81 80 82 87 87 87 88 88 88 97
Research & Development Expense
178 162 170 188 166 165 216 203 187 167 154
Total Other Income / (Expense), net
-4.88 -14 -1.23 -11 -7.00 -6.00 -8.00 -14 -15 -16 -17
Interest Expense
16 16 16 16 14 14 14 19 21 22 20
Interest & Investment Income
13 3.41 11 8.00 7.00 6.00 6.00 6.00 6.00 5.00 3.00
Other Income / (Expense), net
-1.61 -1.83 3.08 -3.61 - 2.00 0.00 -0.93 - 1.00 0.00
Income Tax Expense
0.46 0.86 0.30 -0.02 1.00 1.00 1.00 0.87 1.00 1.00 -9.00
Basic Earnings per Share
($2.03) ($1.52) ($1.40) ($1.34) ($1.57) ($1.17) ($1.81) ($1.28) ($1.84) ($0.90) ($1.16)
Weighted Average Basic Shares Outstanding
84.29M 86.58M 95.49M 90.54M 96.30M 98.50M 99.80M 98.60M 100.60M 101.90M 102.10M
Diluted Earnings per Share
($2.03) ($1.52) ($1.40) ($1.34) ($1.57) ($1.17) ($1.81) ($1.28) ($1.84) ($0.90) ($1.16)
Weighted Average Diluted Shares Outstanding
84.29M 86.58M 95.49M 90.54M 96.30M 98.50M 99.80M 98.60M 100.60M 101.90M 102.10M
Weighted Average Basic & Diluted Shares Outstanding
83.13M 92.17M 92.34M 92.50M 94.54M 96.37M 96.48M 96.63M 98.49M 98.59M 101.92M

Annual Cash Flow Statements for Ultragenyx Pharmaceutical

This table details how cash moves in and out of Ultragenyx Pharmaceutical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
69 69 -62 13 321 290 -417 -172 81 -35 252
Net Cash From Operating Activities
-106 -161 -254 -291 -345 -132 -339 -380 -475 -414 -466
Net Cash From Continuing Operating Activities
-106 -161 -254 -291 -345 -132 -339 -384 -475 -414 -466
Net Income / (Loss) Continuing Operations
-146 -246 -302 -198 -403 -187 -454 -707 -607 -569 -575
Consolidated Net Income / (Loss)
-146 -246 -302 -198 -403 -187 -454 -707 -607 -569 -575
Depreciation Expense
1.38 3.42 5.83 20 8.54 12 13 18 26 36 35
Amortization Expense
5.64 4.84 1.71 -2.64 -6.21 0.85 6.61 2.70 -13 -13 -4.00
Non-Cash Adjustments To Reconcile Net Income
25 50 61 -85 72 3.14 101 246 135 118 101
Changes in Operating Assets and Liabilities, net
7.74 26 -20 -25 -17 38 -5.74 56 -16 14 -23
Net Cash From Investing Activities
-292 91 55 -33 -13 -179 -195 -292 168 -18 236
Net Cash From Continuing Investing Activities
-292 91 55 -33 -13 -179 -195 -292 168 -18 236
Purchase of Property, Plant & Equipment
-4.96 -10 -2.79 -4.08 -25 -44 -73 -116 -44 -7.00 -6.00
Acquisitions
0.00 0.00 -143 0.00 -14 -37 0.00 -105 -3.00 -13 -15
Purchase of Investments
-624 -442 -230 -510 -693 -813 -1,012 -615 -526 -409 -186
Sale and/or Maturity of Investments
338 544 432 310 719 721 891 545 747 413 444
Other Investing Activities, net
-1.54 - - 0.00 0.00 -5.56 -0.94 -0.84 -6.00 -2.00 -1.00
Net Cash From Financing Activities
468 139 136 337 679 600 119 501 388 399 478
Net Cash From Continuing Financing Activities
468 139 136 337 679 600 119 501 388 399 478
Repayment of Debt
0.00 0.00 -4.94 0.00 0.00 -0.24 -0.49 -0.56 1.00 0.00 0.00
Issuance of Common Equity
468 139 141 337 365 601 119 11 387 399 86
Other Financing Activities, net
- - 0.00 0.00 314 0.00 0.00 491 0.00 0.00 392
Effect of Exchange Rate Changes
0.00 -0.07 0.53 - -0.17 1.12 -1.19 -1.08 0.00 -2.00 4.00

Quarterly Cash Flow Statements for Ultragenyx Pharmaceutical

This table details how cash moves in and out of Ultragenyx Pharmaceutical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-97 368 -330 24 -45 49 26 221 -247 -49 24
Net Cash From Operating Activities
-191 -77 -67 -80 -166 -108 -91 -100 -197 -97 -43
Net Cash From Continuing Operating Activities
-191 -77 -67 -80 -166 -108 -91 -100 -197 -97 -43
Net Income / (Loss) Continuing Operations
-171 -132 -134 -133 -151 -115 -180 -129 -185 -92 -118
Consolidated Net Income / (Loss)
-171 -132 -134 -133 -151 -115 -180 -129 -185 -92 -118
Depreciation Expense
8.85 8.86 8.76 9.08 9.00 8.62 8.61 8.79 8.00 8.00 9.00
Non-Cash Adjustments To Reconcile Net Income
31 32 30 25 34 21 26 20 32 16 30
Changes in Operating Assets and Liabilities, net
-56 16 31 23 -56 -22 55 0.59 -51 -29 36
Net Cash From Investing Activities
94 61 -276 103 120 71 117 -72 -49 44 58
Net Cash From Continuing Investing Activities
94 61 -276 103 120 71 117 -72 -49 44 58
Purchase of Property, Plant & Equipment
-3.21 -2.01 -1.62 -0.65 -1.00 -2.46 -1.28 -0.94 -1.00 -1.00 -2.00
Purchase of Investments
-22 -3.37 -367 -16 0.00 -16 -17 -154 -131 -57 -39
Sale and/or Maturity of Investments
132 68 94 119 137 89 136 82 88 105 98
Other Investing Activities, net
-2.07 -0.04 -0.20 -0.13 -1.00 -0.31 -0.19 0.27 0.00 -3.00 1.00
Net Cash From Financing Activities
-0.06 385 11 3.19 0.00 84 0.00 394 0.00 3.00 10
Net Cash From Continuing Financing Activities
-0.06 385 11 3.19 0.00 84 0.00 394 0.00 3.00 10
Effect of Exchange Rate Changes
-0.68 -0.65 1.28 -2.47 1.00 2.91 0.29 -0.66 -1.00 1.00 -1.00

Annual Balance Sheets for Ultragenyx Pharmaceutical

This table presents Ultragenyx Pharmaceutical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
560 541 491 720 1,135 1,760 1,522 1,545 1,491 1,503 1,532
Total Current Assets
450 402 270 522 851 1,295 857 884 732 817 951
Cash & Equivalents
94 161 100 113 434 714 308 133 214 174 421
Short-Term Investments
343 219 134 346 322 488 433 615 364 436 259
Accounts Receivable
- 0.00 5.17 13 33 23 28 40 73 122 158
Inventories, net
- 0.00 0.76 7.07 12 13 16 27 34 45 52
Prepaid Expenses
13 20 29 43 51 58 72 - 48 40 61
Plant, Property, & Equipment, net
7.37 17 22 20 44 74 141 260 291 266 244
Total Noncurrent Assets
102 122 199 177 240 391 525 402 468 420 337
Long-Term Investments
99 118 9.98 0.00 5.17 11 294 149 200 135 57
Goodwill
- 0.00 44 44 44 44 44 44 44 44 44
Intangible Assets
- 0.00 142 129 129 131 131 160 166 178 176
Other Noncurrent Operating Assets
0.60 1.84 3.41 3.51 62 205 55 48 58 63 60
Total Liabilities & Shareholders' Equity
560 541 491 720 1,135 1,760 1,522 1,545 1,491 1,503 1,532
Total Liabilities
28 67 107 111 482 605 600 1,193 1,216 1,241 1,605
Total Current Liabilities
28 60 71 75 103 190 181 261 280 344 384
Accounts Payable
2.94 5.36 8.89 12 13 13 17 43 42 39 31
Accrued Expenses
25 55 62 62 83 108 146 205 196 241 265
Other Current Liabilities
- - - 0.00 7.24 68 19 13 42 64 88
Total Noncurrent Liabilities
0.56 6.39 36 36 378 416 418 932 935 897 1,221
Noncurrent Deferred & Payable Income Tax Liabilities
- 0.00 31 31 33 33 33 32 30 30 30
Other Noncurrent Operating Liabilities
0.56 6.39 5.12 4.76 345 382 385 900 905 867 1,191
Redeemable Noncontrolling Interest
- - - - - - - - 0.00 7.00 7.00
Total Equity & Noncontrolling Interests
531 474 383 609 654 1,154 923 352 275 255 -80
Total Preferred & Common Equity
531 474 383 609 654 1,154 923 352 275 255 -80
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
531 474 383 609 654 1,154 923 352 275 255 -80
Common Stock
817 1,004 1,222 1,640 2,087 2,773 2,998 3,140 3,662 4,213 4,451
Retained Earnings
-285 -531 -833 -1,030 -1,433 -1,620 -2,074 -2,781 -3,388 -3,957 -4,532
Treasury Stock
- - - - - - - 0.00 -0.43 -4.00 -8.00
Accumulated Other Comprehensive Income / (Loss)
-0.87 0.91 -5.68 -0.63 -0.15 0.69 -1.40 -6.57 0.65 -1.00 1.00
Other Equity Adjustments
- - - - - - - 0.00 0.43 4.00 8.00

Quarterly Balance Sheets for Ultragenyx Pharmaceutical

This table presents Ultragenyx Pharmaceutical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
1,311 1,238 1,307 1,618 1,538 1,312 1,306 1,190 1,296 1,264 1,187
Total Current Assets
702 599 596 965 800 699 720 643 657 606 544
Cash & Equivalents
102 73 112 481 151 127 176 203 175 125 150
Short-Term Investments
450 370 300 283 471 367 311 223 238 167 116
Accounts Receivable
71 79 100 106 93 99 124 113 121 200 166
Inventories, net
28 32 36 40 43 46 46 52 55 59 59
Prepaid Expenses
51 46 0.00 - - 60 61 53 68 55 53
Plant, Property, & Equipment, net
289 297 285 279 272 261 256 250 239 235 231
Total Noncurrent Assets
320 342 426 375 466 352 331 297 400 423 412
Long-Term Investments
72 86 157 111 203 69 51 22 121 144 135
Goodwill
44 44 44 44 44 44 44 44 44 44 44
Intangible Assets
158 157 165 166 165 177 175 173 174 172 170
Other Noncurrent Operating Assets
46 54 60 54 54 62 60 58 61 63 63
Total Liabilities & Shareholders' Equity
1,311 1,238 1,307 1,618 1,538 1,312 1,306 1,190 1,296 1,264 1,187
Total Liabilities
1,182 1,206 1,167 1,186 1,185 1,161 1,148 1,174 1,525 1,548 1,556
Total Current Liabilities
244 254 246 273 285 292 293 340 325 351 389
Accounts Payable
42 33 41 60 36 47 34 41 42 39 45
Accrued Expenses
168 179 149 154 185 173 181 221 194 221 242
Other Current Liabilities
35 42 55 59 64 71 78 79 89 91 102
Total Noncurrent Liabilities
938 952 921 913 900 869 855 834 1,200 1,197 1,167
Noncurrent Deferred & Payable Income Tax Liabilities
32 32 30 30 30 30 30 30 30 30 21
Other Noncurrent Operating Liabilities
906 921 891 883 869 839 825 804 1,170 1,167 1,146
Redeemable Noncontrolling Interest
- - - - 7.00 7.00 7.00 7.00 7.00 7.00 7.00
Total Equity & Noncontrolling Interests
129 32 140 432 347 144 151 9.16 -236 -291 -376
Total Preferred & Common Equity
129 32 140 432 347 144 151 9.16 -236 -291 -376
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
129 32 140 432 347 144 151 9.16 -236 -291 -376
Common Stock
3,237 3,298 3,699 4,123 4,169 4,253 4,374 4,412 4,481 4,518 4,552
Retained Earnings
-3,105 -3,264 -3,558 -3,690 -3,823 -4,108 -4,223 -4,403 -4,717 -4,809 -4,927
Treasury Stock
-0.38 -0.38 -3.33 -3.40 -3.56 -7.57 -7.99 -7.99 -10 -10 -10
Accumulated Other Comprehensive Income / (Loss)
-3.10 -2.24 -0.43 -1.10 0.90 -0.34 -0.27 0.82 0.00 0.00 -1.00
Other Equity Adjustments
0.38 0.38 3.33 3.40 3.56 7.57 7.99 7.99 10 10 10

Annual Metrics And Ratios for Ultragenyx Pharmaceutical

This table displays calculated financial ratios and metrics derived from Ultragenyx Pharmaceutical's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 1,863.91% 1,871.48% 101.41% 161.32% 29.66% 3.39% 19.52% 29.01% 20.18%
EBITDA Growth
-151.07% -71.28% -30.46% 39.74% -122.74% 25.14% -14.91% -73.16% 11.62% 7.08% 2.90%
EBIT Growth
-144.89% -68.74% -29.16% 35.91% -105.65% 22.46% -16.36% -69.65% 12.44% 5.20% 1.29%
NOPAT Growth
-160.20% -67.87% -32.63% -12.90% -14.22% 22.17% -15.64% -69.99% 12.28% 5.84% 0.19%
Net Income Growth
-143.50% -68.85% -22.88% 34.60% -103.80% 53.67% -143.36% -55.81% 14.25% 6.17% -1.05%
EPS Growth
-76.00% -56.82% -14.65% 44.24% -79.35% 56.88% -118.24% -51.04% 18.48% 23.76% 7.31%
Operating Cash Flow Growth
-137.44% -51.90% -57.69% -14.47% -18.87% 61.72% -156.16% -12.33% -24.80% 12.77% -12.56%
Free Cash Flow Firm Growth
-170.01% -54.59% -158.66% 31.92% 84.80% -581.75% 23.81% 89.93% -1,951.27% 10.62% 87.94%
Invested Capital Growth
-126.75% -270.74% 603.14% 7.35% -171.47% 45.93% -93.35% -388.14% 7.82% 3.78% -67.70%
Revenue Q/Q Growth
0.00% 3.91% 1,186.70% 36.78% 22.91% 26.01% -2.27% 5.81% 5.86% 7.17% 6.72%
EBITDA Q/Q Growth
-37.13% -7.42% -8.81% 3.92% -1.26% 0.44% -1.48% -7.66% 4.53% -0.76% 2.64%
EBIT Q/Q Growth
-36.06% -6.86% -8.96% 3.89% -0.95% -0.45% -1.91% -6.99% 4.28% -1.10% 2.14%
NOPAT Q/Q Growth
-36.14% -6.16% -8.68% 1.72% -0.98% -0.50% -1.73% -7.11% 3.98% -0.04% 1.65%
Net Income Q/Q Growth
-35.92% -6.99% -3.58% -3.18% -1.51% 27.23% -27.69% -4.33% 4.51% -1.82% 0.83%
EPS Q/Q Growth
-34.69% -4.90% -2.01% 2.70% 2.33% 30.07% -28.35% -4.01% 8.13% 1.56% 1.02%
Operating Cash Flow Q/Q Growth
-35.89% -4.71% -15.54% 8.20% -4.92% 6.76% 2.34% -10.45% 1.34% 1.05% -4.56%
Free Cash Flow Firm Q/Q Growth
-36.80% -2.76% -99.07% 40.85% 87.90% -237.43% 46.31% -192.68% 4.06% 1.62% 88.70%
Invested Capital Q/Q Growth
-23.69% -36.50% 524.54% -6.46% -152.00% 74.78% -18.73% -0.56% -1.05% -2.52% -87.87%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 100.00% 99.96% 97.77% 91.31% 97.74% 95.44% 92.21% 89.59% 86.30% 83.80%
EBITDA Margin
0.00% -181,475.19% -12,055.17% -368.47% -407.50% -116.74% -103.46% -173.28% -128.12% -92.29% -74.74%
Operating Margin
0.00% -186,471.43% -12,593.49% -721.18% -408.98% -121.80% -108.63% -178.60% -131.08% -95.67% -79.49%
EBIT Margin
0.00% -187,690.23% -12,343.49% -401.28% -409.74% -121.58% -109.11% -179.03% -131.16% -96.38% -79.35%
Profit (Net Income) Margin
0.00% -184,867.67% -11,567.34% -383.75% -388.31% -68.84% -129.20% -194.71% -139.70% -101.60% -85.44%
Tax Burden Percent
100.00% 100.01% 94.91% 100.26% 100.82% 100.65% 100.23% 100.81% 99.70% 100.28% 100.70%
Interest Burden Percent
98.43% 98.48% 98.74% 95.38% 94.00% 56.25% 118.14% 107.88% 106.83% 105.12% 106.93%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% -413.53% -180.41% -1,395.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% -394.26% -198.12% -1,377.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 343.06% 140.58% 1,331.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-40.67% -48.93% -70.48% -39.83% -63.79% -20.64% -43.72% -110.96% -193.23% -211.71% -608.47%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% -285.55% -187.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% -45.38% -62.52% -34.15% -45.82% -22.76% -23.37% -42.41% -37.51% -36.06% -35.19%
Return on Assets (ROA)
0.00% -44.70% -58.59% -32.65% -43.42% -12.89% -27.67% -46.12% -39.96% -38.02% -37.89%
Return on Common Equity (ROCE)
-40.67% -48.93% -70.48% -39.83% -63.79% -20.64% -43.72% -110.96% -193.23% -208.95% -563.39%
Return on Equity Simple (ROE_SIMPLE)
-27.42% -51.88% -78.79% -32.45% -61.60% -16.16% -49.21% -200.69% -220.26% -222.95% 0.00%
Net Operating Profit after Tax (NOPAT)
-103 -174 -230 -260 -297 -231 -267 -454 -398 -375 -375
NOPAT Margin
0.00% -130,530.00% -8,815.44% -504.83% -286.29% -85.26% -76.04% -125.02% -91.76% -66.97% -55.65%
Net Nonoperating Expense Percent (NNEP)
-11.61% -13.90% -19.27% 17.71% -17.34% 4.51% -16.63% -26.23% -24.88% -25.49% -27.06%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - -128.87% -144.67% -146.96% 468.13%
Cost of Revenue to Revenue
0.00% 0.00% 0.04% 2.23% 8.69% 2.26% 4.56% 7.79% 10.41% 13.70% 16.20%
SG&A Expenses to Revenue
0.00% 48,824.06% 3,825.00% 248.03% 155.74% 67.50% 62.60% 76.55% 71.34% 57.41% 51.86%
R&D to Revenue
0.00% 137,747.37% 8,868.45% 570.93% 344.56% 152.04% 141.48% 194.26% 149.33% 124.57% 111.44%
Operating Expenses to Revenue
0.00% 186,571.43% 12,693.45% 818.96% 500.30% 219.54% 204.08% 270.81% 220.67% 181.97% 163.30%
Earnings before Interest and Taxes (EBIT)
-148 -250 -322 -207 -425 -330 -383 -650 -570 -540 -534
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-141 -241 -315 -190 -423 -316 -364 -630 -556 -517 -503
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
8.20 6.06 5.15 3.61 3.77 7.32 6.21 9.21 14.26 15.22 0.00
Price to Tangible Book Value (P/TBV)
8.20 6.06 10.00 5.05 5.14 8.63 7.67 21.95 60.66 119.25 0.00
Price to Revenue (P/Rev)
0.00 21,600.43 756.23 42.71 23.79 31.18 16.31 8.94 9.04 6.93 3.30
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 12.45 11.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 17,844.62 662.64 33.78 16.46 26.71 13.37 6.47 7.25 5.62 2.21
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.02 -1.03 -0.87 -0.71 -0.97 -1.09 -1.08 -1.51 -2.67 -2.83 -7.84
Leverage Ratio
1.06 1.09 1.20 1.22 1.47 1.60 1.58 2.41 4.84 5.57 16.06
Compound Leverage Factor
1.04 1.08 1.19 1.16 1.38 0.90 1.87 2.60 5.17 5.85 17.17
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.67% -9.59%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 97.33% 109.59%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
91.10 23.72 6.99 9.79 0.95 7.38 3.76 -1.56 -1.85 -2.24 -3.58
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.30% 7.41%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
16.13 6.67 3.80 6.99 8.24 6.83 4.72 3.38 2.61 2.37 2.48
Quick Ratio
15.65 6.31 3.37 6.32 7.63 6.46 4.24 3.02 2.32 2.13 2.18
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-99 -153 -397 -270 -41 -280 -213 -21 -441 -394 -48
Operating Cash Flow to CapEx
-2,138.79% -1,580.05% -9,088.54% -7,128.70% -1,390.88% -301.15% -463.38% -327.64% -1,072.60% -5,529.14% -7,766.67%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 -36.19 -8.41 -7.25 -0.50 -6.68 -6.25 -0.77
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 -304.30 -3.97 -11.51 -8.84 -7.19 -6.57 -7.52
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 -326.18 -5.29 -14.00 -11.54 -7.86 -6.69 -7.61
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.01 0.09 0.11 0.19 0.21 0.24 0.29 0.37 0.44
Accounts Receivable Turnover
0.00 0.00 0.00 5.75 4.55 9.69 13.64 10.55 7.63 5.74 4.81
Inventory Turnover
0.00 0.00 0.00 0.29 0.97 0.50 1.09 1.32 1.49 1.94 2.25
Fixed Asset Turnover
0.00 0.01 0.13 2.46 3.22 4.60 3.27 1.81 1.58 2.01 2.64
Accounts Payable Turnover
0.00 0.00 0.00 0.11 0.72 0.48 1.07 0.94 1.06 1.90 3.11
Days Sales Outstanding (DSO)
0.00 0.00 0.00 63.48 80.21 37.67 26.76 34.60 47.84 63.59 75.93
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 1,245.65 377.05 732.32 333.80 277.08 245.18 187.85 162.41
Days Payable Outstanding (DPO)
0.00 0.00 2,600,625.00 3,369.88 509.45 768.05 342.71 389.31 344.69 192.35 117.20
Cash Conversion Cycle (CCC)
0.00 0.00 -2,600,625.00 -2,060.75 -52.19 1.93 17.84 -77.63 -51.68 59.08 121.14
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-7.45 -28 139 149 -107 -58 -111 -544 -502 -483 -810
Invested Capital Turnover
0.00 -0.01 0.05 0.36 4.87 -3.30 -4.15 -1.11 -0.83 -1.14 -1.04
Increase / (Decrease) in Invested Capital
-4.17 -20 167 10 -256 49 -54 -433 43 19 -327
Enterprise Value (EV)
3,820 2,373 1,731 1,739 1,707 7,238 4,698 2,351 3,150 3,147 1,489
Market Capitalization
4,356 2,873 1,975 2,199 2,467 8,450 5,732 3,248 3,927 3,885 2,219
Book Value per Share
$13.68 $11.60 $9.00 $12.04 $11.32 $18.91 $13.53 $5.03 $3.35 $2.76 ($0.83)
Tangible Book Value per Share
$13.68 $11.60 $4.64 $8.61 $8.31 $16.04 $10.96 $2.11 $0.79 $0.35 ($3.11)
Total Capital
531 474 383 609 654 1,154 923 352 275 262 -73
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-536 -500 -244 -460 -760 -1,212 -1,034 -897 -777 -745 -737
Capital Expenditures (CapEx)
4.96 10 2.79 4.08 25 44 73 116 44 7.49 6.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-15 -40 -36 -12 -7.51 -96 -65 -125 -125 -137 -113
Debt-free Net Working Capital (DFNWC)
422 341 199 448 748 1,106 675 623 452 473 567
Net Working Capital (NWC)
422 341 199 448 748 1,106 675 623 452 473 567
Net Nonoperating Expense (NNE)
42 72 72 -62 106 -45 187 253 208 194 201
Net Nonoperating Obligations (NNO)
-539 -502 -244 -460 -760 -1,212 -1,034 -897 -777 -745 -737
Total Depreciation and Amortization (D&A)
7.02 8.27 7.53 17 2.33 13 20 21 13 23 31
Debt-free, Cash-free Net Working Capital to Revenue
0.00% -30,167.67% -1,375.34% -23.42% -7.24% -35.36% -18.49% -34.42% -28.89% -24.46% -16.79%
Debt-free Net Working Capital to Revenue
0.00% 256,718.80% 7,602.18% 869.30% 720.94% 407.96% 192.15% 171.38% 104.03% 84.42% 84.25%
Net Working Capital to Revenue
0.00% 256,718.80% 7,602.18% 869.30% 720.94% 407.96% 192.15% 171.38% 104.03% 84.42% 84.25%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($3.96) ($6.21) ($7.12) ($3.97) ($7.12) ($3.07) ($6.70) ($10.12) ($8.25) ($6.29) ($5.83)
Adjusted Weighted Average Basic Shares Outstanding
38.98M 41.73M 49.61M 51.28M 57.89M 66.95M 69.38M 69.91M 73.54M 90.54M 98.60M
Adjusted Diluted Earnings per Share
($3.96) ($6.21) ($7.12) ($3.97) ($7.12) ($3.07) ($6.70) ($10.12) ($8.25) ($6.29) ($5.83)
Adjusted Weighted Average Diluted Shares Outstanding
38.98M 41.73M 49.61M 51.28M 57.89M 66.95M 69.38M 69.91M 73.54M 90.54M 98.60M
Adjusted Basic & Diluted Earnings per Share
($3.96) ($6.21) ($7.12) ($3.97) ($7.12) ($3.07) ($6.70) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
36.78M 39.59M 42.45M 49.78M 56.58M 60.85M 67.80M 70.22M 82.34M 92.50M 96.63M
Normalized Net Operating Profit after Tax (NOPAT)
-103 -174 -230 -260 -297 -231 -267 -454 -398 -375 -375
Normalized NOPAT Margin
0.00% -130,530.00% -8,815.44% -504.83% -286.29% -85.26% -76.04% -125.02% -91.76% -66.97% -55.65%
Pre Tax Income Margin
0.00% -184,841.35% -12,187.52% -382.75% -385.14% -68.39% -128.91% -193.14% -140.12% -101.31% -84.84%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 -374.41 -9.90 -13.03 -15.12 -8.63 -8.56 -8.61
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 -261.60 -6.94 -9.08 -10.56 -6.04 -5.95 -6.04
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 -396.29 -11.22 -15.52 -17.82 -9.30 -8.68 -8.71
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 -283.48 -8.26 -11.57 -13.26 -6.71 -6.07 -6.14
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Ultragenyx Pharmaceutical

This table displays calculated financial ratios and metrics derived from Ultragenyx Pharmaceutical's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - - - - - 96,629,788.00 98,489,224.00 98,588,873.00
DEI Adjusted Shares Outstanding
- - - - - - - - 96,629,788.00 98,489,224.00 98,588,873.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - -1.91 -0.93 -1.20
Growth Metrics
- - - - - - - - - - -
Revenue Growth
8.30% 35.75% 42.27% 29.42% 27.99% 13.24% 14.65% 25.89% -2.16% 28.14% 8.13%
EBITDA Growth
-6.80% 24.04% 12.75% -3.35% 16.69% 12.56% -33.07% 12.14% -19.12% 32.65% 38.41%
EBIT Growth
-8.55% 21.18% 11.58% -4.90% 14.88% 10.53% -33.37% 10.03% -18.18% 30.19% 35.67%
NOPAT Growth
-7.30% 21.35% 9.04% -0.19% 13.55% 7.28% -29.47% 7.38% -18.18% 30.56% 35.67%
Net Income Growth
-4.09% 17.66% 16.37% -8.28% 11.49% 12.65% -35.12% 3.49% -22.52% 20.00% 34.44%
EPS Growth
12.88% 32.44% 37.22% 6.94% 22.66% 23.03% -29.29% 4.48% -17.20% 23.08% 35.91%
Operating Cash Flow Growth
-21.59% 33.74% 43.16% 5.25% 12.72% -40.68% -36.46% -25.86% -18.67% 11.01% 52.75%
Free Cash Flow Firm Growth
-149.90% -136.94% 19.32% 18.30% 37.47% -2.00% -35.01% 337.47% 299.54% 309.43% 264.26%
Invested Capital Growth
14.20% 10.65% 5.16% 3.78% 3.88% 13.87% 8.43% -67.70% -85.30% -89.10% -78.59%
Revenue Q/Q Growth
-14.57% 35.09% -5.12% 18.20% -15.52% 19.53% -3.94% 29.60% -34.39% 57.35% -19.16%
EBITDA Q/Q Growth
-39.86% 30.64% -9.79% 2.97% -12.74% 27.19% -67.08% 35.41% -52.91% 59.26% -53.03%
EBIT Q/Q Growth
-39.12% 29.21% -9.07% 2.35% -12.88% 25.58% -62.59% 33.57% -47.96% 56.21% -48.65%
NOPAT Q/Q Growth
-35.48% 29.63% -13.43% 7.36% -16.90% 24.52% -58.40% 33.71% -49.18% 55.62% -46.67%
Net Income Q/Q Growth
-38.55% 22.90% -1.46% 0.10% -13.27% 23.91% -56.95% 28.74% -43.91% 50.27% -28.26%
EPS Q/Q Growth
-40.97% 25.12% 7.89% 4.29% -17.16% 25.48% -54.70% 29.28% -43.75% 51.09% -28.89%
Operating Cash Flow Q/Q Growth
-127.32% 59.65% 12.95% -18.67% -109.39% 34.96% 15.56% -9.19% -97.34% 50.76% 55.67%
Free Cash Flow Firm Q/Q Growth
-45.83% 28.11% 12.04% 11.40% -11.61% -17.26% -16.44% 255.46% -5.96% 23.10% -8.68%
Invested Capital Q/Q Growth
14.61% -3.19% -6.51% -2.52% 14.70% 7.53% -13.24% -87.87% 5.80% 5.64% -6.94%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
83.89% 85.53% 84.93% 89.75% 79.42% 86.18% 82.50% 85.84% 77.94% 84.11% 81.50%
EBITDA Margin
-148.73% -76.36% -88.37% -72.55% -96.81% -58.97% -102.56% -51.11% -119.12% -30.84% -58.38%
Operating Margin
-151.93% -79.14% -94.62% -74.16% -102.62% -64.80% -106.85% -54.65% -124.26% -35.05% -63.58%
EBIT Margin
-153.40% -80.39% -92.41% -76.35% -102.02% -63.51% -107.50% -55.10% -124.26% -34.58% -63.58%
Profit (Net Income) Margin
-156.83% -89.51% -95.71% -80.90% -108.46% -69.04% -112.81% -62.02% -136.03% -42.99% -68.21%
Tax Burden Percent
100.27% 100.66% 100.23% 99.99% 100.87% 100.83% 100.49% 100.68% 100.54% 101.10% 92.91%
Interest Burden Percent
101.96% 110.62% 103.34% 105.97% 105.40% 107.81% 104.42% 111.79% 108.88% 122.97% 115.45%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-340.05% -208.43% -289.98% -211.71% -377.06% -180.44% -313.43% -608.47% 1,566.48% 932.27% 297.02%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-50.47% -26.41% -34.80% -28.57% -46.02% -26.50% -49.69% -24.44% -63.85% -19.29% -39.05%
Return on Assets (ROA)
-51.60% -29.41% -36.04% -30.27% -48.93% -28.81% -52.14% -27.51% -69.89% -23.99% -41.89%
Return on Common Equity (ROCE)
-340.05% -208.43% -284.71% -208.95% -368.00% -178.30% -301.57% -563.39% 1,848.53% 1,036.10% 308.80%
Return on Equity Simple (ROE_SIMPLE)
-437.28% -135.31% -161.17% 0.00% -381.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-116 -81 -92 -86 -100 -76 -120 -79 -118 -53 -77
NOPAT Margin
-106.35% -55.40% -66.23% -51.91% -71.83% -45.36% -74.80% -38.26% -86.99% -24.53% -44.51%
Net Nonoperating Expense Percent (NNEP)
-8.53% -6.69% -6.08% -6.28% -9.02% -5.58% -9.56% -6.65% -12.16% -8.10% -9.67%
Return On Investment Capital (ROIC_SIMPLE)
- - - -33.53% -69.37% -49.92% -1,306.07% 99.12% 50.13% 18.04% 20.48%
Cost of Revenue to Revenue
16.11% 14.47% 15.07% 10.25% 20.58% 13.82% 17.50% 14.16% 22.06% 15.89% 18.50%
SG&A Expenses to Revenue
71.82% 54.82% 57.60% 50.03% 63.03% 52.04% 54.16% 42.42% 64.71% 41.12% 56.07%
R&D to Revenue
164.00% 109.85% 121.95% 113.88% 119.01% 98.94% 135.19% 98.07% 137.50% 78.04% 89.02%
Operating Expenses to Revenue
235.82% 164.67% 179.55% 163.92% 182.04% 150.98% 189.35% 140.50% 202.21% 119.16% 145.09%
Earnings before Interest and Taxes (EBIT)
-167 -118 -129 -126 -142 -106 -172 -114 -169 -74 -110
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-162 -112 -123 -120 -135 -98 -164 -106 -162 -66 -101
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
27.33 7.90 14.76 15.22 23.22 22.72 316.50 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 15.41 37.24 119.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
8.66 7.10 9.79 6.93 5.67 5.63 4.60 3.30 3.02 4.59 2.03
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
7.38 5.28 8.23 5.62 4.73 4.76 3.90 2.21 2.23 3.99 1.49
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 91.07
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-3.57 -2.67 -3.51 -2.83 -3.88 -2.39 -3.44 -7.84 14.11 7.76 2.40
Leverage Ratio
7.46 5.22 7.20 5.57 8.98 4.95 7.38 16.06 -33.54 -20.45 -6.74
Compound Leverage Factor
7.60 5.77 7.44 5.90 9.47 5.34 7.70 17.95 -36.52 -25.14 -7.78
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 1.98% 2.67% 4.63% 4.42% 43.32% -9.59% -3.06% -2.46% -1.90%
Common Equity to Total Capital
100.00% 100.00% 98.02% 97.33% 95.37% 95.58% 56.68% 109.59% 103.06% 102.46% 101.90%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-1.60 -0.89 -0.42 -1.33 -2.19 -2.14 -3.34 -2.67 -3.91 -3.44 -4.77
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 1.82% 1.30% 2.40% 1.19% 3.78% 7.41% -18.01% -11.14% -3.97%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.43 3.54 2.81 2.37 2.40 2.45 1.89 2.48 2.02 1.73 1.40
Quick Ratio
2.09 3.19 2.51 2.13 2.03 2.09 1.58 2.18 1.64 1.40 1.11
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-187 -134 -118 -105 -117 -137 -159 248 233 287 262
Operating Cash Flow to CapEx
-5,939.80% -3,830.91% -4,143.17% -12,156.42% -12,573.64% -4,401.34% -7,153.60% -10,642.75% -19,700.00% -9,700.00% -2,150.00%
Free Cash Flow to Firm to Interest Expense
-11.78 -8.41 -7.51 -6.74 -8.14 -9.75 -11.26 12.72 11.09 13.03 13.09
Operating Cash Flow to Interest Expense
-12.04 -4.82 -4.26 -5.12 -11.61 -7.71 -6.46 -5.13 -9.38 -4.41 -2.15
Operating Cash Flow Less CapEx to Interest Expense
-12.24 -4.95 -4.37 -5.16 -11.70 -7.89 -6.55 -5.18 -9.43 -4.45 -2.25
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.33 0.33 0.38 0.37 0.45 0.42 0.46 0.44 0.51 0.56 0.61
Accounts Receivable Turnover
6.18 5.45 6.06 5.74 5.93 5.30 6.13 4.81 6.10 4.42 5.24
Inventory Turnover
1.61 1.81 1.91 1.94 2.14 2.07 2.02 2.25 2.18 2.29 2.25
Fixed Asset Turnover
1.57 1.70 1.84 2.01 2.16 2.28 2.41 2.64 2.68 2.92 3.04
Accounts Payable Turnover
1.01 1.21 2.07 1.90 1.99 1.90 2.52 3.11 2.46 3.30 2.92
Days Sales Outstanding (DSO)
59.07 66.93 60.25 63.59 61.51 68.93 59.57 75.93 59.88 82.59 69.64
Days Inventory Outstanding (DIO)
226.02 201.80 190.75 187.85 170.20 176.50 180.58 162.41 167.62 159.12 162.35
Days Payable Outstanding (DPO)
361.32 300.74 176.06 192.35 183.67 191.61 144.72 117.20 148.41 110.47 124.94
Cash Conversion Cycle (CCC)
-76.24 -32.01 74.94 59.08 48.04 53.82 95.43 121.14 79.10 131.24 107.05
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-428 -442 -471 -483 -412 -381 -431 -810 -763 -720 -770
Invested Capital Turnover
-0.95 -1.03 -1.08 -1.14 -1.41 -1.48 -1.40 -1.04 -1.14 -1.30 -1.22
Increase / (Decrease) in Invested Capital
71 53 26 19 17 61 40 -327 -351 -339 -339
Enterprise Value (EV)
3,265 2,542 4,302 3,147 2,793 2,906 2,459 1,489 1,497 2,860 1,088
Market Capitalization
3,834 3,417 5,120 3,885 3,349 3,438 2,899 2,219 2,024 3,289 1,482
Book Value per Share
$1.66 $5.20 $3.76 $2.76 $1.56 $1.60 $0.10 ($0.83) ($2.44) ($2.95) ($3.81)
Tangible Book Value per Share
($0.82) $2.67 $1.49 $0.35 ($0.83) ($0.72) ($2.16) ($3.11) ($4.70) ($5.15) ($5.98)
Total Capital
140 432 354 262 151 158 16 -73 -229 -284 -369
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-569 -874 -825 -745 -563 -539 -447 -737 -534 -436 -401
Capital Expenditures (CapEx)
3.21 2.01 1.62 0.65 1.32 2.46 1.28 0.94 1.00 1.00 2.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-62 -72 -107 -137 -87 -61 -122 -113 -81 -37 -111
Debt-free Net Working Capital (DFNWC)
350 692 515 473 407 427 303 567 332 255 155
Net Working Capital (NWC)
350 692 515 473 407 427 303 567 332 255 155
Net Nonoperating Expense (NNE)
55 50 41 48 51 39 61 49 67 40 41
Net Nonoperating Obligations (NNO)
-569 -874 -825 -745 -563 -539 -447 -737 -534 -436 -401
Total Depreciation and Amortization (D&A)
5.09 5.92 5.64 6.27 7.26 7.57 7.90 8.27 7.00 8.00 9.00
Debt-free, Cash-free Net Working Capital to Revenue
-13.94% -14.97% -20.47% -24.46% -14.72% -10.00% -19.36% -16.79% -12.09% -5.16% -15.21%
Debt-free Net Working Capital to Revenue
79.17% 143.73% 98.44% 84.42% 68.99% 69.91% 48.08% 84.25% 49.55% 35.56% 21.23%
Net Working Capital to Revenue
79.17% 143.73% 98.44% 84.42% 68.99% 69.91% 48.08% 84.25% 49.55% 35.56% 21.23%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($2.03) ($1.52) ($1.40) ($1.34) ($1.57) ($1.17) ($1.81) ($1.28) ($1.84) ($0.90) ($1.16)
Adjusted Weighted Average Basic Shares Outstanding
84.29M 86.58M 95.49M 90.54M 96.29M 98.46M 99.77M 98.60M 100.60M 101.90M 102.10M
Adjusted Diluted Earnings per Share
($2.03) ($1.52) ($1.40) ($1.34) ($1.57) ($1.17) ($1.81) ($1.28) ($1.84) ($0.90) ($1.16)
Adjusted Weighted Average Diluted Shares Outstanding
84.29M 86.58M 95.49M 90.54M 96.29M 98.46M 99.77M 98.60M 100.60M 101.90M 102.10M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
83.13M 92.17M 92.34M 92.50M 94.54M 96.37M 96.48M 96.63M 98.49M 98.59M 101.92M
Normalized Net Operating Profit after Tax (NOPAT)
-116 -81 -92 -86 -100 -76 -120 -79 -118 -53 -77
Normalized NOPAT Margin
-106.35% -55.40% -66.23% -51.91% -71.83% -45.36% -74.80% -38.26% -86.99% -24.53% -44.51%
Pre Tax Income Margin
-156.41% -88.92% -95.50% -80.91% -107.52% -68.47% -112.26% -61.60% -135.29% -42.52% -73.41%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-10.54 -7.41 -8.20 -8.11 -9.91 -7.53 -12.15 -5.87 -8.05 -3.36 -5.50
NOPAT to Interest Expense
-7.30 -5.10 -5.88 -5.51 -6.98 -5.38 -8.46 -4.07 -5.63 -2.39 -3.85
EBIT Less CapEx to Interest Expense
-10.74 -7.53 -8.31 -8.15 -10.00 -7.71 -12.24 -5.91 -8.10 -3.41 -5.60
NOPAT Less CapEx to Interest Expense
-7.51 -5.23 -5.98 -5.56 -7.07 -5.55 -8.55 -4.12 -5.68 -2.43 -3.95
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Ultragenyx Pharmaceutical’s latest results show improving revenue momentum and a narrower operating loss, but the company remains unprofitable and continues to consume cash. In Q2 2026, revenue reached $214 million, up from $136 million in Q1 2026 and $167 million in Q2 2025. This was the highest quarterly revenue in the provided data. Gross profit increased to $180 million, producing an approximately 84% gross margin.

Operating performance also improved sequentially. The operating loss narrowed to $75 million in Q2 2026 from $169 million in Q1, helped by higher revenue and lower research and development spending. However, net income attributable to common shareholders remained negative at $92 million, or $0.90 per diluted share. The company has reported losses in every quarterly income statement provided.

The balance sheet presents a more mixed picture. Ultragenyx had $125 million of cash and equivalents and $167 million of short-term investments at June 30, 2026, plus $144 million of long-term investments. Nevertheless, operating cash flow remained negative, and reported shareholders’ equity was negative $291 million because total liabilities exceeded total assets. Investors should also account for restated and calculated figures in portions of the historical data when comparing periods.

  • Revenue growth is encouraging: Q2 2026 revenue of $214 million was approximately 28% higher than Q2 2025 and more than double Q3 2022 revenue of $91 million.
  • Gross margins remain strong: The Q2 2026 gross margin was approximately 84%, despite cost of revenue rising to $34 million.
  • Sequential operating improvement: The operating loss narrowed from $169 million in Q1 2026 to $75 million in Q2, while total operating expenses fell from $275 million to $255 million.
  • Research spending moderated: R&D expense declined to $167 million in Q2 2026 from $187 million in Q1, helping reduce the quarterly loss while the company continued investing in its pipeline.
  • Liquidity remains meaningful: Cash, short-term investments and long-term investments totaled approximately $436 million at the end of Q2 2026, providing resources to fund operations and development activities.
  • Cash flow benefited from investment activity: Investing activities generated $44 million in Q2 2026, primarily because $105 million of investments were sold or matured. This supported cash, but may not represent recurring operating strength.
  • Quarterly revenue is volatile: Revenue rose to $207 million in Q4 2025, fell to $136 million in Q1 2026 and then rebounded to $214 million in Q2. Investors should be cautious about extrapolating one quarter’s performance.
  • Operating cash burn continues: Net cash used in operating activities was $97 million in Q2 2026. Although this was an improvement from $197 million in Q1, continued negative operating cash flow increases reliance on existing liquidity or future financing.
  • Persistent net losses remain a major risk: Ultragenyx reported a $92 million net loss in Q2 2026 and has not reached profitability in any of the periods supplied.
  • Negative reported equity and dilution warrant attention: Shareholders’ equity was negative $291 million in Q2 2026, compared with positive equity in earlier periods. Weighted-average basic shares increased to 101.9 million from 70.4 million in Q1 2023, indicating substantial dilution over the period.
11/16/26 08:14 PM ETAI Generated. May Contain Errors.

Ultragenyx Pharmaceutical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Ultragenyx Pharmaceutical's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Ultragenyx Pharmaceutical's net income appears to be on a downward trend, with a most recent value of -$575 million in 2025, falling from -$145.62 million in 2015. The previous period was -$569 million in 2024. See Ultragenyx Pharmaceutical's forecast for analyst expectations on what's next for the company.

Ultragenyx Pharmaceutical's total operating income in 2025 was -$535 million, based on the following breakdown:
  • Total Gross Profit: $564 million
  • Total Operating Expenses: $1.10 billion

Over the last 10 years, Ultragenyx Pharmaceutical's total revenue changed from $0.00 in 2015 to $673 million in 2025, a change of 67,300,000,000.0%.

In the past 13 quarters, Ultragenyx Pharmaceutical's cash and equivalents has ranged from $72.58 million in Q3 2023 to $480.69 million in Q2 2024, and is currently $150 million as of their latest financial filing in Q3 2026.

Ultragenyx Pharmaceutical had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2015.

Over the last 10 years, Ultragenyx Pharmaceutical's book value per share changed from 13.68 in 2015 to -0.83 in 2025.



Financial statements for NASDAQ:RARE last updated on 11/4/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners